Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21799450 | 0.82 | MMP8 (0.39) | KDM4EKDM1AANPEPERAP2PIM1 | |
| SCHEMBL21799533 | 0.79 | KDM4E (0.34) | KDM4EKDM1AANPEPERAP2PIM1 | |
| SCHEMBL21799566 | 0.78 | KDM1A (0.33) | KDM4EKDM1AANPEPERAP2PIM1 | |
| SCHEMBL21799919 | 0.77 | KDM1A (0.33) | KDM4EKDM1AANPEPERAP2 | |
| SCHEMBL17802174 | 0.75 | KDM4E (0.35) | KDM4EANPEPERAP2 | |
| SCHEMBL17802175 | 0.75 | KDM4E (0.35) | KDM4EANPEPERAP2 | |
| SCHEMBL16538131 | 0.74 | KDM4E (0.60) | KDM4EANPEPERAP2 | |
| SCHEMBL30198223 | 0.74 | KDM1A (0.36) | KDM1APIM1 | |
| SCHEMBL21799558 | 0.74 | KDM1A (0.31) | KDM4EKDM1A | |
| Hydrochloric Acid SCHEMBL17802228 | 0.74 | KDM4E (0.34) | KDM4EANPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| US-20230085912-A1 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230085912-A1 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | KDM4E 1841/4885KDM1A 3809/4885ANPEP 159/4885 |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | KDM4E 1841/4885KDM1A 3809/4885ANPEP 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.